Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma

NCT06562673 is registered in ClinicalTrials.gov with Shanghai 6th People's Hospital as lead sponsor.

NCT NCT06562673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06562673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma
Lead sponsor
Shanghai 6th People's Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
December 3, 2024
Completion date
July 20, 2025
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bone cancer, osteosarcoma